StockNews.com began coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Free Report) (TSE:AEZ) in a research note published on Wednesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Aeterna Zentaris Price Performance
NASDAQ AEZS opened at $3.69 on Wednesday. The firm has a market capitalization of $6.62 million, a P/E ratio of -0.25 and a beta of 1.55. Aeterna Zentaris has a 1-year low of $3.96 and a 1-year high of $12.00. The business’s 50-day simple moving average is $4.13 and its 200-day simple moving average is $5.92.
Aeterna Zentaris Company Profile
Read More
- Five stocks we like better than Aeterna Zentaris
- Buy P&G Now, Before It Sets A New All-Time High
- Texas Roadhouse Stock Steering for New Highs This Year
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- What is the Nikkei 225 index?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.